The Pathogenesis of Systemic Sclerosis

Rheumatic Disease Clinics of North America

Volumn 41, Issue 3, 2015, Pages 367-382

  Stern, Edward P ^a   Denton, Christopher P ^a  

^a Hypermobility Clinic   (United Kingdom)

Author keywords

Autoimmunity; Fibrosis; Pathogenesis; Scleroderma; Systemic sclerosis; Vasculopathy

Indexed keywords

AUTOANTIBODY; CHEMOKINE; CONNECTIVE TISSUE GROWTH FACTOR; CXCL4 CHEMOKINE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR A; ENDOTHELIN RECEPTOR B; HLA ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; INTERLEUKIN DERIVATIVE; VASOCONSTRICTOR AGENT;

CELLULAR IMMUNITY; COLLAGEN SYNTHESIS; CONNECTIVE TISSUE DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HIGH RISK POPULATION; HORMONE RESPONSE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; INTRACELLULAR SIGNALING; LUNG FIBROBLAST; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAYNAUD PHENOMENON; REVIEW; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; COMPLICATION; ENDOCRINE SYSTEM; FEMALE; FIBROBLAST; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY; INFECTION; NEOPLASM; PHYSIOLOGY; SCLERODERMA, SYSTEMIC;

AUTOANTIBODIES; CHEMOKINES; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINES; DISEASE PROGRESSION; ENDOCRINE SYSTEM; FEMALE; FIBROBLASTS; GENOME-WIDE ASSOCIATION STUDY; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; INFECTION; INTERLEUKINS; NEOPLASMS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; VASOCONSTRICTOR AGENTS;

EID: 84937974685     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.04.002     Document Type: Review

References (103)

1. Agarwal S.K., Tan F.K., Arnett F.C. Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am 2008, 34:17-40. v.
2. Feghali-Bostwick C., Medsger T.A., Wright T.M. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003, 48:1956-1963.
3. Tan F.K., Arnett F.C. Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon. Curr Opin Rheumatol 2000, 12:511-519.
4. Tan F.K. Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 2003, 29:211-237.
5. Morel P.A., Chang H.J., Wilson J.W., et al. HLA and ethnic associations among systemic sclerosis patients with anticentromere antibodies. Hum Immunol 1995, 42:35-42.
6. Reveille J.D., Durban E., MacLeod-St Clair M.J., et al. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest 1992, 90:973-980.
7. Gilchrist F.C., Bunn C., Foley P.J., et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun 2001, 2:76-81.
8. Fatini C., Gensini F., Sticchi E., et al. High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med 2002, 112:540-544.
9. Fonseca C., Renzoni E., Sestini P., et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum 2006, 54:3034-3042.
10. Fonseca C., Lindahl G.E., Ponticos M., et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007, 357:1210-1220.
11. Tan F.K., Stivers D.N., Foster M.W., et al. Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum 1998, 41:1729-1737.
12. Zhou X., Tan F.K., Reveille J.D., et al. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum 2002, 46:2990-2999.
13. Rueda B., Broen J., Simeon C., et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009, 18:2071-2077.
14. Rueda B., Gourh P., Broen J., et al. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann Rheum Dis 2010, 69:700-705.
15. Dieudé P., Guedj M., Wipff J., et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009, 60:225-233.
16. Dieudé P., Guedj M., Wipff J., et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009, 60:2472-2479.
17. Radstake T.R., Gorlova O., Rueda B., et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat. Genet. 2010, 42:426-429.
18. Allanore Y., Saad M., Dieudé P., et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 2011, 7:e1002091.
19. Gorman C.L., Russell A.I., Zhang Z., et al. Polymorphisms in the CD3Z gene influence TCRzeta expression in systemic lupus erythematosus patients and healthy controls. J. Immunol 2008, 180:1060-1070.
20. Gorlova O., Martin J.E., Rueda B., et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet 2011, 7:e1002178.
21. Guerra S.G., Fonseca C., Nihtyanova S.I., et al. Defining Genetic Risk for Scleroderma Renal Crisis: A Genome-Wide Analysis of Anti-Rna Polymerase Antibody-Positive Systemic Sclerosis. Br Soc Rheumatol 2015, 54(Suppl 1):i159.
22. Binns C.H. Vinyl chloride: a review. J Soc Occup Med 1979, 29:134-141.
23. Black C.M., Welsh K.I., Walker A.E., et al. Genetic susceptibility to scleroderma-like syndrome induced by vinyl chloride. Lancet 1983, 1:53-55.
24. Black C., Pereira S., McWhirter A., et al. Genetic susceptibility to scleroderma-like syndrome in symptomatic and asymptomatic workers exposed to vinyl chloride. J Rheumatol 1986, 13:1059-1062.
25. Itoh M., Yanaba K., Kobayashi T., et al. Taxane-induced scleroderma. Br J Dermatol 2007, 156:363-367.
26. Tabuenca J.M. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 1981, 2:567-568.
27. Silver R.M., Heyes M.P., Maize J.C., et al. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med 1990, 322:874-881.
28. Nietert P.J., Sutherland S.E., Silver R.M., et al. Is occupational organic solvent exposure a risk factor for scleroderma?. Arthritis Rheum 1998, 41:1111-1118.
29. Marie I., Gehanno J.F., Bubenheim M., et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev 2014, 13:151-156.
30. Kettaneh A., Al Moufti O., Tiev K.P., et al. Occupational exposure to solvents and gender-related risk of systemic sclerosis: a metaanalysis of case-control studies. J Rheumatol 2007, 34:97-103.
31. Shi-Wen X., Panesar M., Vancheeswaran R., et al. Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen. Arthritis Rheum 1994, 37:1689-1697.
32. Maul G.G., Jimenez S.A., Riggs E., et al. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc Natl Acad Sci U S A 1989, 86:8492-8496.
33. Lunardi C., Bason C., Navone R., et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000, 6:1183-1186.
34. Shah A.A., Rosen A., Hummers L., et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010, 62:2787-2795.
35. Moinzadeh P., Fonseca C., Hellmich M., et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014, 16:R53.
36. Joseph C.G., Darrah E., Shah A.A., et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014, 343:152-157.
37. Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. Lancet 1996, 347:1453-1458.
38. Pearson J.D. The endothelium: its role in scleroderma. Ann Rheum Dis 1991, 50(Suppl 4):866-871.
39. Flavahan N.A., Flavahan S., Liu Q., et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000, 43:1886-1890.
40. Levin E.R. Endothelins. N Engl J Med 1995, 333:356-363.
41. Kahaleh M.B. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991, 34:978-983.
42. Yamane K., Miyauchi T., Suzuki N., et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992, 19:1566-1571.
43. Vancheeswaran R., Magoulas T., Efrat G., et al. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction?. J Rheumatol 1994, 21:1838-1844.
44. Kobayashi H., Nishimaki T., Kaise S., et al. Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol 1999, 18:425-427.
45. Penn H., Quillinan N., Khan K., et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 2013, 106(9):839-848.
46. Vancheeswaran R., Azam A., Black C., et al. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994, 21:1268-1276.
47. Rolla G., Colagrande P., Scappaticci E., et al. Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension. J Rheumatol 2000, 27:1693-1698.
48. Andersen G.N., Caidahl K., Kazzam E., et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000, 43:1085-1093.
49. Ibba-Manneschi L., Niissalo S., Milia A.F., et al. Variations of neuronal nitric oxide synthase in systemic sclerosis skin. Arthritis Rheum 2006, 54:202-213.
50. Carvalho D., Savage C.O., Black C.M., et al. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 1996, 97:111-119.
51. Sgonc R., Gruschwitz M.S., Boeck G., et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000, 43:2550-2562.
52. Ahmed S.S., Tan F.K., Arnett F.C., et al. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 2006, 54:2250-2262.
53. Sprott H., Müller-Ladner U., Distler O., et al. Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J Rheumatol 2000, 27:402-404.
54. Grote K., Flach I., Luchtefeld M., et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res 2003, 92:e80-e86.
55. Riccieri V., Spadaro A., Fuksa L., et al. Specific oxidative stress parameters differently correlate with nailfold capillaroscopy changes and organ involvement in systemic sclerosis. Clin Rheumatol 2008, 27:225-230.
56. Kuwana M., Okazaki Y., Yasuoka H., et al. Defective vasculogenesis in systemic sclerosis. Lancet 2004, 364:603-610.
57. Mulligan-Kehoe M.J., Drinane M.C., Mollmark J., et al. Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 2007, 56:3448-3458.
58. Springer T.A. Adhesion receptors of the immune system. Nature 1990, 346:425-434.
59. Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999, 11:503-507.
60. Gruschwitz M., von den Driesch P., Kellner I., et al. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992, 27:169-177.
61. Carson C.W., Beall L.D., Hunder G.G., et al. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 1993, 20:809-814.
62. Sfikakis P.P., Tesar J., Baraf H., et al. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 1993, 68:88-92.
63. Stratton R.J., Coghlan J.G., Pearson J.D., et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 1998, 91:561-566.
64. Casciola-Rosen L., Wigley F., Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 1997, 185:71-79.
65. Chizzolini C., Raschi E., Rezzonico R., et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002, 46:1602-1613.
66. Riemekasten G., Philippe A., Näther M., et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011, 70:530-536.
67. Baroni S.S., Santillo M., Bevilacqua F., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
68. Stummvoll G.H., Aringer M., Grisar J., et al. Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis 2004, 63:569-574.
69. Roumm A.D., Whiteside T.L., Medsger T.A., et al. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984, 27:645-653.
70. Brent J., McMartin K., Phillips S., et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group. N Engl J Med 1999, 340:832-838.
71. Murata M., Fujimoto M., Matsushita T., et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?. J Dermatol Sci 2008, 50:240-242.
72. Radstake T.R., van Bon L., Broen J., et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009, 4:e5903.
73. Antiga E., Quaglino P., Bellandi S., et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 2010, 162:1056-1063.
74. York M.R. Novel insights on the role of the innate immune system in systemic sclerosis. Expert Rev Clin Immunol 2011, 7:481-489.
75. Bhattacharyya S., Kelley K., Melichian D.S., et al. Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 2013, 182:192-205.
76. Abraham D., Lupoli S., McWhirter A., et al. Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 1991, 34:1164-1172.
77. Higley H., Persichitte K., Chu S., et al. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994, 37:278-288.
78. Corrin B., Butcher D., McAnulty B.J., et al. Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994, 24:145-150.
79. Dziadzio M., Smith R.E., Abraham D.J., et al. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) 2005, 44:1518-1524.
80. Kubo M., Ihn H., Yamane K., et al. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001, 44:731-734.
81. McWhirter A., Colosetti P., Rubin K., et al. Collagen type I is not under autocrine control by transforming growth factor-beta 1 in normal and scleroderma fibroblasts. Lab. Invest 1994, 71:885-894.
82. Yamakage A., Kikuchi K., Smith E.A., et al. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992, 175:1227-1234.
83. Leask A., Holmes A., Abraham D.J. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep 2002, 4:136-142.
84. Dziadzio M., Usinger W., Leask A., et al. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM 2005, 98:485-492.
85. Shi-wen X., Stanton L.A., Kennedy L., et al. CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. J Biol Chem 2006, 281:10715-10726.
86. Andersen M.B., Pingel J., Kjær M., et al. Interleukin-6: a growth factor stimulating collagen synthesis in human tendon. J Appl Physiol 2011, 110:1549-1554.
87. Sato S., Hasegawa M., Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001, 27:140-146.
88. Salmon-Ehr V., Serpier H., Nawrocki B., et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 1996, 132:802-806.
89. Needleman B.W., Wigley F.M., Stair R.W. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992, 35:67-72.
90. Distler J.H., Jüngel A., Caretto D., et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006, 54:214-225.
91. Aden N., Nuttall A., Shiwen X., et al. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. J Invest Dermatol 2010, 130:2191-2200.
92. Romagnani P., Maggi L., Mazzinghi B., et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol 2005, 116:1372-1379.
93. van Bon L., Affandi A.J., Broen J., et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014, 370:433-443.
94. Carulli M.T., Ong V.H., Ponticos M., et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005, 52:3772-3782.
95. Shi-Wen X., Denton C.P., McWhirter A., et al. Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum 1997, 40:1237-1244.
96. Kähäri V.M., Sandberg M., Kalimo H., et al. Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 1988, 90:664-670.
97. Scharffetter K., Lankat-Buttgereit B., Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988, 18:9-17.
98. Denton C.P., Khan K., Hoyles R.K., et al. Inducible lineage-specific deletion of TbetaRII in fibroblasts defines a pivotal regulatory role during adult skin wound healing. J Invest Dermatol 2009, 129:194-204.
99. Hoyles R.K., Derrett-Smith E.C., Khan K., et al. An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor. Am J Respir Crit Care Med 2011, 183:249-261.
100. LeRoy E.C., Mercurio S., Sherer G.K. Replication and phenotypic expression of control and scleroderma human fibroblasts: responses to growth factors. Proc Natl Acad Sci U S A 1982, 79:1286-1290.
101. Wang Y., Fan P.-S., Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006, 54:2271-2279.
102. Wallis D.D., Tan F.K., Kielty C.M., et al. Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum 2001, 44:1855-1864.
103. Lemaire R., Farina G., Kissin E., et al. Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril-associated glycoprotein 2 and type I collagen. Arthritis Rheum 2004, 50:915-926.